Dianwen Han

2.0k total citations · 1 hit paper
26 papers, 1.0k citations indexed

About

Dianwen Han is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Dianwen Han has authored 26 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 16 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Dianwen Han's work include Circular RNAs in diseases (12 papers), MicroRNA in disease regulation (10 papers) and Cancer-related molecular mechanisms research (10 papers). Dianwen Han is often cited by papers focused on Circular RNAs in diseases (12 papers), MicroRNA in disease regulation (10 papers) and Cancer-related molecular mechanisms research (10 papers). Dianwen Han collaborates with scholars based in China. Dianwen Han's co-authors include Qifeng Yang, Bing Chen, Yaming Li, Wenjing Zhao, Yiran Liang, Hanwen Zhang, Ying Liu, Xiaojin Song, Ning Zhang and Chen Li and has published in prestigious journals such as Oncogene, Cell Death and Differentiation and Molecular Cancer.

In The Last Decade

Dianwen Han

25 papers receiving 1.0k citations

Hit Papers

circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer
    2019 340 citations Yuting Sang, Bing Chen et al. Molecular Therapy profile →

Peers

Dianwen Han
Qiaozhu Zuo China
Mingli Han China
Pınar Kanlikilicer United States
Hong‐Li Jiao China
Elisa Penna Italy
Ya‐Wen Wang China
Xueliang Zuo China
Qiaozhu Zuo China
Dianwen Han
Citations per year, relative to Dianwen Han Dianwen Han (= 1×) peers Qiaozhu Zuo

Countries citing papers authored by Dianwen Han

Since Specialization
Citations

This map shows the geographic impact of Dianwen Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dianwen Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dianwen Han more than expected).

Fields of papers citing papers by Dianwen Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dianwen Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dianwen Han. The network helps show where Dianwen Han may publish in the future.

Co-authorship network of co-authors of Dianwen Han

This figure shows the co-authorship network connecting the top 25 collaborators of Dianwen Han. A scholar is included among the top collaborators of Dianwen Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dianwen Han. Dianwen Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Han, Dianwen, Lijuan Wang, Shan Jiang, et al.. (2025). The USP1-WDR48 deubiquitinase complex functions as a molecular switch regulating tumor-associated macrophage activation and anti-tumor response. Cell Death and Differentiation. 33(1). 92–110.
3.
Chen, Xi, Yaming Li, Yiran Liang, et al.. (2024). COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk. Oncogene. 43(23). 1742–1756. 10 indexed citations
4.
Li, Yaming, Yiran Liang, Tong Chen, et al.. (2024). Trim21-mediated CCT2 ubiquitination suppresses malignant progression and promotes CD4+T cell activation in breast cancer. Cell Death and Disease. 15(7). 542–542. 7 indexed citations
5.
Li, Long, Lei Wang, Yiran Liang, et al.. (2024). UGCG promotes chemoresistance and breast cancer progression via NF-κB and Wnt/β-catenin pathway activation. Translational Oncology. 52. 102241–102241. 2 indexed citations
6.
Liang, Yiran, Fangzhou Ye, Li Long, et al.. (2024). Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer. Molecular Cancer. 23(1). 125–125. 20 indexed citations
7.
Li, Yaming, H. J. Yang, Yuhan Sun, et al.. (2024). CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation‐Mediated c‐Myc Deubiquitylation to Facilitate Mutant TP53 Transcription. Advanced Science. 11(34). e2404628–e2404628. 14 indexed citations
8.
Liang, Yiran, Yajie Wang, Yan Zhang, et al.. (2023). HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-κB signaling pathway in breast cancer. Cell Death and Disease. 14(7). 434–434. 62 indexed citations
9.
Han, Dianwen, Lijuan Wang, Shan Jiang, & Qifeng Yang. (2023). The ubiquitin–proteasome system in breast cancer. Trends in Molecular Medicine. 29(8). 599–621. 50 indexed citations
10.
Ye, Fangzhou, Yiran Liang, Yajie Wang, et al.. (2023). Cancer-associated fibroblasts facilitate breast cancer progression through exosomal circTBPL1-mediated intercellular communication. Cell Death and Disease. 14(7). 471–471. 37 indexed citations
11.
Luo, Dan, Yiran Liang, Yajie Wang, et al.. (2023). Long non-coding RNA MIDEAS-AS1 inhibits growth and metastasis of triple-negative breast cancer via transcriptionally activating NCALD. Breast Cancer Research. 25(1). 115–138. 5 indexed citations
12.
Song, Xiaojin, Bing Chen, Yiran Liang, et al.. (2022). CircEIF3H-IGF2BP2-HuR scaffold complex promotes TNBC progression via stabilizing HSPD1/RBM8A/G3BP1 mRNA. Cell Death Discovery. 8(1). 261–261. 14 indexed citations
13.
Wang, Xiaolong, Chen Li, Tong Chen, et al.. (2021). Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients. Frontiers in Oncology. 11. 660242–660242. 8 indexed citations
14.
Li, Zheng, Yaming Li, Xiaolong Wang, et al.. (2021). LINC01977 Promotes Breast Cancer Progression and Chemoresistance to Doxorubicin by Targeting miR-212-3p/GOLM1 Axis. Frontiers in Oncology. 11. 657094–657094. 16 indexed citations
15.
Liang, Yiran, Fangzhou Ye, Yajie Wang, et al.. (2021). DGUOK-AS1 acts as a tumor promoter through regulating miR-204-5p/IL-11 axis in breast cancer. Molecular Therapy — Nucleic Acids. 26. 1079–1091. 13 indexed citations
16.
Liang, Yiran, Xiaojin Song, Yaming Li, et al.. (2021). Correction: circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene. 40(15). 2816–2816. 2 indexed citations
17.
Li, Yaming, Zekun Wang, Peng Su, et al.. (2021). circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway. Molecular Therapy. 30(1). 415–430. 133 indexed citations
18.
Liu, Ying, Ning Zhang, Hanwen Zhang, et al.. (2020). <p>Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer</p>. Drug Design Development and Therapy. Volume 14. 3535–3545. 17 indexed citations
19.
Sang, Yuting, Bing Chen, Xiaojin Song, et al.. (2019). circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Molecular Therapy. 27(9). 1638–1652. 340 indexed citations breakdown →
20.
Liang, Yiran, Xiaojin Song, Yaming Li, et al.. (2019). circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene. 38(42). 6850–6866. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiaozhu Zuo Breakdown of academic impact, for papers by Mingli Han Breakdown of academic impact, for papers by Pınar Kanlikilicer Breakdown of academic impact, for papers by Hong‐Li Jiao Breakdown of academic impact, for papers by Elisa Penna Breakdown of academic impact, for papers by Ya‐Wen Wang Breakdown of academic impact, for papers by Xueliang Zuo
Rankless by CCL
2026